Consultant at N2Pharma LLC (2010-01 – Present)
- Industry consultant working on key formulation and material issue for pharmaceutical industry customers.
- Projects: 1. new lubricant for industry leader in excipients reporting to Global market director 2. setting up new Neutraceutical production facility, SOP development, formulations, ISO, etc. 3. Developed formulations for clients as well as audited production facilities to verify cGMP for CFR 21 part 111.
VP Operations at Nuovo Biologics LLC (2010-01 – 2014-01)
- Opened new cGLP laboratory and production site; selection, equipment procurement, IQ,OQ,PQ instillation, SOP development, method development and validation, etc.
- Responsible for CMC section development for new peptide API, working with FDA.
Director of Research & Development at Avema Pharma Solutions (2003-01 – 2010-01)
- Head of all formulations and research. Marketing support and technical service.
- Developed over 50 formulations per week for contracting company.
- Responsible for all new technology developments.
- Five patents applied for.
- Developed over 9M formulations in 7 years.
- 2009 formulated and developed 22 OTC products and transferred 9 to production through validation.
- Presentations to all key retail clients.
- Set up cGMP systems for part 211 and 111 to coexist in the same plant, including cleaning validation, process validation, stability programs, etc.
- Developed two new technologies for key disease states, potential sales 250MM.
- Set up phase one, two clinical trials.
Director of Business Development at LONZA BIOLOGICALS (2002-01 – 2003-01)
- Develop and service biotechnology accounts in the Northeast region of the US providing services in API production via bacterial fermentation processes.
- Anticancer, Antibiotic, natural products including clinical trials.
Vice President International and Marketing at PARTICLE DYNAMICS, INC. (1996-01 – 2002-01)
- Responsible for finding, training and supporting a global distributor and agent network for PDI with contracts that are supportable.
- This includes the development of a support group for the region via technical support, product development and new product introductions.
- Set up 36 distributors covering 56 key target countries under contracts.
- Trained all distributors and agents in two years.
- Doubled sales in first year in region then again year three to four, and year five.
- Introduced and developed 10 new products via various technologies.
- Supported two clinical trials external.
- A $25million value-added product supplier wholly owned by K-V Pharmaceuticals, a $200 million U.S. pharmaceutical company.
Director of Marketing at PARTICLE DYNAMICS, INC. (1992-01 – 1996-01)
- Responsible for $9 million product line and all aspects of marketing; such as new product development; market development; advertising/promotion; new product launches; pricing and sales coordination.
- International duties include support of distributor network, sales development and regional expansion.
- Developed 12 new products and diversified the product line from one material to 10 reducing competition and creating specialty products for the market(effervescent, Chewable tablets, etc).
- Created global sales support strategy for an expanded distribution network resulting in a 200% increase to $1.6 million in one year.
- Positioned PDI to the pharmaceutical industry as a technology leader by creating a high profile through technical literature and services, industry support and advertising.
- A $25million value-added product supplier wholly owned by K-V Pharmaceuticals, a $200 million U.S. pharmaceutical company.
Global Market Manager (Pharmaceuticals) at GAF(ISP) CORPORATION (1988-01 – 1992-01)
- Responsible for reviewing and developing new global markets; developing and implementing global market plans; targeting and launching new products and creating P&L statements for market groups of a $110 million product line.
- Developed an international sales training program for 125 sales personnel; enhanced capabilities helped launch 9 new products in two years.
- Increased sales from $75 million to $110 million via a strategic global advertising and account campaign.
- Defined and targeted two new global market niches($5 million veterinary and $8 million dental segments).
- Defined 6 new materials for use in neutraceutical field.
- An $800 million specialty company with $120 million annual revenues from pharmaceutical chemicals.
Market Specialist (Pharmaceuticals) at GAF(ISP) CORPORATION (1985-01 – 1988-01)
- Researched market segments for high value products; coordinated R&D and Tech Service; developed new products, literature and sales leads; targeted markets for existing products.
- Converted pharmaceutical division from regional to market segment focus; created coordinated global effort which increased international sales 65% to $35 million.
- Developed 10 new products yielding $38 million in annual sales with 80% gross profit margins.
- Set up company's first Tech Service systems and organized first sales training function.
- An $800 million specialty company with $120 million annual revenues from pharmaceutical chemicals.
Senior Product Manager (Acetylenes) at GAF(ISP) CORPORATION (1983-01 – 1985-01)
- Responsible for product management functions for $10 million line of 15 products.
- Positioned GAF as a supplier of choice for the pharmaceutical industry by comprehensive promotion activities, Tech Service, and a first ever advertising campaign.
- Developed mailing lists of pharmaceutical industry for sales follow-up to ad responses, increasing business from $10 million to $35 million within two years.
- An $800 million specialty company with $120 million annual revenues from pharmaceutical chemicals.
Production Supervisor (Liquids and Ointments) at LEDERLE LABS (1982-01 – 1983-01)
- Responsible for production of $1.5 million in pharmaceutical products per month.
- Coordinated 5 departments and supervised 10 hourly union personnel.
- Improved department performance from a $90,000 deficit to a $395,000, profit in one year.
- Reduced manpower 35% while increasing output 200% via technology and resource allocation.
- A $1 billion pharmaceutical division of American Cyanamid, a $2.5 billion multinational corporation.
Senior Research Scientist (Process Improvement) at LEDERLE LABS (1979-01 – 1982-01)
- Formulation transfer from R&D, reworks and current line products, this included formulating the original Centrum, Caltrate, Stresstab and Geverbon line of vitamins and minerals using D/C technology vs Granulation.
- Created alternate raw material vendor program saving $1.4 million annually.
- Set up system for new vendor qualification.
- Received numerous commendations and service awards.
- A $1 billion pharmaceutical division of American Cyanamid, a $2.5 billion multinational corporation.
